Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) Income from Continuing Operations (2022 - 2025)

Bioregenx has reported Income from Continuing Operations over the past 4 years, most recently at 1017805.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 94.47% year-over-year to 1017805.0; the TTM value through Dec 2025 reached 1543569.0, up 92.51%, while the annual FY2025 figure was 1543569.0, 93.3% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 1017805.0 at Bioregenx, down from 80565.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 2191.0 in Q3 2022 and troughed at 18400571.0 in Q4 2024.
  • A 4-year average of 1449116.56 and a median of 204091.5 in 2023 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: crashed 26695.74% in 2024 and later surged 94.47% in 2025.
  • Year by year, Income from Continuing Operations stood at 5535.0 in 2022, then plummeted by 12907.52% to 719966.0 in 2023, then tumbled by 2455.76% to 18400571.0 in 2024, then surged by 94.47% to 1017805.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BRGX at 1017805.0 in Q4 2025, 80565.0 in Q3 2025, and 178345.0 in Q2 2025.